Foghorn Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Foghorn Therapeutics es Adrian H. Gottschalk , nombrado en May 2017, tiene una permanencia de 7.5 años. compensación anual total es $2.50M, compuesta por 23.1% salario y 76.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.92% de las acciones de la empresa, por valor de $4.01M. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 7.3 años, respectivamente.
Información clave
Adrian H. Gottschalk
Chief Executive Officer (CEO)
US$2.5m
Compensación total
| Porcentaje del salario del CEO | 23.1% |
| Permanencia del CEO | 7.5yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | 1.2yrs |
| Promedio de permanencia en la Junta Directiva | 7.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk
Oct 22Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up
Sep 01Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking
Jul 17Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$91m |
| Jun 30 2024 | n/a | n/a | -US$86m |
| Mar 31 2024 | n/a | n/a | -US$93m |
| Dec 31 2023 | US$3m | US$579k | -US$98m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$5m | US$575k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$105m |
| Dec 31 2021 | US$4m | US$540k | -US$101m |
| Sep 30 2021 | n/a | n/a | -US$93m |
| Jun 30 2021 | n/a | n/a | -US$85m |
| Mar 31 2021 | n/a | n/a | -US$78m |
| Dec 31 2020 | US$3m | US$479k | -US$69m |
| Sep 30 2020 | n/a | n/a | -US$63m |
| Jun 30 2020 | n/a | n/a | -US$58m |
| Mar 31 2020 | n/a | n/a | -US$54m |
| Dec 31 2019 | US$1m | US$465k | -US$51m |
Compensación vs. Mercado: La compensación total ($USD2.50M) de Adrian H. está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.14M).
Compensación vs. Ingresos: La compensación de Adrian H. ha sido consistente con los resultados de la empresa en el último año.
CEO
Adrian H. Gottschalk (48 yo)
7.5yrs
Permanencia
US$2,503,942
Compensación
Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.5yrs | US$2.50m | 0.92% $ 4.0m | |
| Chief Scientific Officer | 2.8yrs | US$1.19m | 0.27% $ 1.2m | |
| Chief Medical Officer | 1.2yrs | US$1.84m | sin datos | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Chief of Staff to the CEO | no data | sin datos | sin datos | |
| Chief Legal Officer | 4yrs | US$1.99m | 0% $ 0 | |
| Vice President of Corporate Development | 2.8yrs | sin datos | sin datos | |
| Chief People Officer | no data | sin datos | sin datos | |
| Chief Business Officer | less than a year | sin datos | sin datos | |
| VP & Chief of Staff Research | less than a year | sin datos | sin datos |
1.2yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de FHTX no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.5yrs | US$2.50m | 0.92% $ 4.0m | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 2.3yrs | US$157.65k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$159.07k | 0.061% $ 267.0k | |
| Founder & Independent Chairman of the Board | 9.1yrs | US$184.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.3yrs | US$153.07k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$154.57k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$145.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.2yrs | US$252.52k | 6.52% $ 28.4m |
7.3yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de FHTX se considera experimentada (7.3 años de antigüedad promedio).